SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Vector illustration of pig in graphic style. Drawing by hand.
Drug Development
Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants
It’s early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions to make this approach a viable option and help ease the organ shortage crisis.
March 24, 2025
 · 
8 min read
 · 
Kate Goodwin
3D illustration abstract background. Image of puzzle pieces in chrome gray metal.
GLP-1
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like cardiovascular and sleep apnea—may prove a greater market advantage.
March 17, 2025
 · 
6 min read
 · 
Kate Goodwin
Drug addiction concept, depressed woman with medicine pills. Medical health care and pharmaceutical vector illustration
Obesity
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment.
March 10, 2025
 · 
5 min read
 · 
Kate Goodwin
high contrast image of Judge gavel on a blue wooden background
Legal
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied the compounders’ injunction.
March 6, 2025
 · 
3 min read
 · 
Kate Goodwin
Balance. Sphere. Scale. 3d illustration.
Obesity
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate an evolving mindset toward treating obesity as a chronic disease.
March 3, 2025
 · 
7 min read
 · 
Kate Goodwin
Business
Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover key topics for the lobbying group, including the Inflation Reduction Act.
February 20, 2025
 · 
2 min read
 · 
Kate Goodwin
Businessman climbed the clouds to see the distance
Immunology and Inflammation
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.
February 17, 2025
 · 
5 min read
 · 
Kate Goodwin
AbbVie's office in South San Francisco, California
Deals
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B
The pharma giant inked its third T cell engager deal of 2025 Wednesday—this time with Xilio Therapeutics for tumor-activated immunotherapies.
February 12, 2025
 · 
1 min read
 · 
Kate Goodwin
Financial Crisis Concept. Bankrupt Businessman Character Stand at Sinking Paper Ship Waving White Flag in Sea with scatter Dollar Bills and Coins Business Man Bankruptcy. Cartoon Vector Illustration
Layoffs
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.
February 4, 2025
 · 
1 min read
 · 
Kate Goodwin
Back view of disabled teenager in wheelchair looking out window, having depression at home, copy space. Paraplegic teen boy feeling stressed and upset, suffering from loneliness indoors
Duchenne muscular dystrophy
5 DMD Candidates to Watch in 2025
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.
January 27, 2025
 · 
6 min read
 · 
Kate Goodwin
Histology microscope image of motor unit synapse of muscle fibers (100x)
Duchenne muscular dystrophy
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.
January 27, 2025
 · 
8 min read
 · 
Kate Goodwin
Cancer cells
Cancer
Reframing Multiple Myeloma: From Fatal to Chronic and Even Curable
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs.
January 21, 2025
 · 
8 min read
 · 
Kate Goodwin
Drug Development
Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.
January 14, 2025
 · 
1 min read
 · 
Kate Goodwin
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
 · 
5 min read
 · 
Kate Goodwin
Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering
Cardiovascular disease
Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb
Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.
January 10, 2025
 · 
1 min read
 · 
Kate Goodwin
Load More